表紙
市場調查報告書

關注市場分析:急性非補償性心臟衰竭 (ADHF)

Market Spotlight: Acute Decompensated Heart Failure (ADHF)

出版商 Datamonitor Healthcare 商品編碼 858253
出版日期 內容資訊 英文 33 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:急性非補償性心臟衰竭 (ADHF) Market Spotlight: Acute Decompensated Heart Failure (ADHF)
出版日期: 2019年11月21日內容資訊: 英文 33 Pages
簡介

本報告提供全球急性非補償性心臟衰竭 (ADHF)的市場調查,疾病的背景、流行病學,診斷及治療選擇,主要的已上市藥,臨床試驗、開發平台趨勢,授權、資產取得等企業間趨勢,商機分析等彙整資料。

概要

要點

疾病背景

  • 定義
  • 症狀
  • 患者的亞型
  • 風險要素
  • 診斷

治療

  • 利尿劑
  • 血管擴張劑
  • 超過濾 (UF)
  • 強心藥
  • 鈉利尿肽
  • 升壓藥/乙型阻斷劑/ACE抑制劑(血管收縮素轉換酵素抑制劑)
  • 循環輔助設備
  • 其他

流行病學

  • 罹患率

已上市藥物

開發平台藥物

近幾年趨勢、分析師的見解

今後主要的活動

成功的概率

授權、資產取得交易

商機

臨床試驗趨勢

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0203494

This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, epidemiology information, licensing and asset acquisition deals, and drug-specific revenues.

Key Takeaways

Approved drugs in the acute decompensated heart failure (ADHF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C. All of the approved therapies are administered via the intravenous route, with two drugs also being available in an oral formulation.

The majority of industry-sponsored drugs in active clinical development for ADHF are in Phase II. Therapies in development for ADHF focus on targets such as Na-K-Cl cotransporter, corticotropin releasing factor - receptor2, guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum Ca2+-ATPase, troponin, vasopressin receptors, and phosphodiesterase

9. These therapies are administered via the oral, intravenous, and subcutaneous routes.

High-impact upcoming events for drugs in the ADHF space comprise topline Phase II trial results for BMS-986231 and Istaroxime.

The overall likelihood of approval of a Phase I ADHF asset is 1.8%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 12.9 years from Phase I to approval, compared to 10.0 years in the overall cardiovascular space.

There have been only two licensing and asset acquisition deals involving ADHF drugs during 2014-19. The $2,075m acquisition of Cardioxyl by Bristol-Myers Squibb in 2015, which also gave the company full rights to Cardioxyl's lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in Phase II clinical development as an intravenous treatment for ADHF, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ADHF have been in the late phases of development, with 57% of trials in Phase III-IV, and 43% in Phase I-II.

Clinical trial activity in the ADHF space is dominated by completed trials. Johnson & Johnson has the highest number of completed clinical trials for ADHF, with 17 trials.

Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for ADHF, followed by Novartis.

TABLE OF CONTENTS

CONTENTS

5 OVERVIEW

6 KEY TAKEAWAYS

7 DISEASE BACKGROUND

7 Definition

7 Symptoms

7 Patient subtypes

7 Risk factors

7 Diagnosis

9 TREATMENT

9 Diuretics

9 Vasodilator therapy

10 Ultrafiltration (UF)

10 Inotropes

10 Natriuretic peptides

10 Vasopressors/Beta blockers/ACE inhibitors

11 Circulatory assist devices

11 Other therapies

12 EPIDEMIOLOGY

12 ADHF incidence

13 MARKETED DRUGS

15 PIPELINE DRUGS

19 RECENT EVENTS AND ANALYST OPINION

19 Reprieve-Guided Diuretic Therapy for ADHF (December 15, 2018)

19 WhiteSwell Therapy System for ADHF (December 11, 2018)

21 Entresto for ADHF (November 11, 2018)

23 KEY UPCOMING EVENTS

24 PROBABILITY OF SUCCESS

25 LICENSING AND ASSET ACQUISITION DEALS

26 CLINICAL TRIAL LANDSCAPE

27 Sponsors by status

28 Sponsors by phase

30 BIBLIOGRAPHY

30 Prescription information

32 APPENDIX

LIST OF FIGURES

  • 15 Figure 1: Overview of pipeline drugs for ADHF in the US
  • 15 Figure 2: Pipeline drugs for ADHF, by company
  • 16 Figure 3: Pipeline drugs for ADHF, by drug type
  • 16 Figure 4: Pipeline drugs for ADHF, by classification
  • 22 Figure 5: Entresto for ADHF (November 11, 2018): Phase IV - PIONEER-HF
  • 23 Figure 6: Key upcoming events in ADHF
  • 24 Figure 7: Probability of success in the ADHF pipeline
  • 25 Figure 8: Licensing and asset acquisition deals in ADHF, 2014-19
  • 26 Figure 9: Clinical trials in ADHF
  • 26 Figure 10: Top 10 drugs for clinical trials in ADHF
  • 27 Figure 11: Top 10 companies for clinical trials in ADHF
  • 28 Figure 12: ADHF trials status
  • 29 Figure 13: ADHF trials sponsors, by phase

LIST OF TABLES

  • 14 Table 1: Marketed drugs for ADHF
  • 17 Table 2: Pipeline drugs for ADHF in the US
  • 19 Table 3: Reprieve-Guided Diuretic Therapy for ADHF (December 15, 2018)
  • 20 Table 4: WhiteSwell Therapy System for ADHF (December 11, 2018)
  • 21 Table 5: Entresto for ADHF (November 11, 2018)
Back to Top